ALK still has two horses in adrenaline race

ALK has two cards up its sleeve in its efforts to take shares of the adrenaline market. However, its in-house developed pen and partner Windgap's product may end up running heats for a spot in the final, as CEO Carsten Hellmann says they will "probably choose one at some point."
Carsten Hellmann, CEO of ALK | Photo: Gregers Tycho/Ritzau/Ritzau Scanpix
Carsten Hellmann, CEO of ALK | Photo: Gregers Tycho/Ritzau/Ritzau Scanpix
by albert rønning-andersoon, translated by catherine brett

Allergy specialist firm ALK has still got two horses in the race to become the leading adrenaline pen distributor in the US.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading